{"entity":{"id":"nct07157033","kind":"trial","name":"A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.","aka":[],"tldr":"A phase 1/2 trial of XER-001 in pancreatic ductal adenocarcinoma, run by Xerient Pharma, now recruiting.","summary":"A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer. is a phase 1/2 interventional study registered as NCT07157033 by Xerient Pharma, with 36 participants planned, started 2026-01-01 and due to reach its primary completion in 2029-07-31. Interventions recorded: XER-001.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07157033","url":"https://clinicaltrials.gov/study/NCT07157033"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","locally-advanced-pdac"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":["amifostine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07157033","phase":"1/2","setting":"A Phase 1/2a, Open Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of XER-001 (Amifostibe for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment of Locally-Advanced Pancreatic Adenocarcinoma","sponsor":"Xerient Pharma","participation":[{"nct":"NCT07157033","source":"https://clinicaltrials.gov/study/NCT07157033","fetchedAt":"2026-10-07T16:55:29.886Z","studySha256":"300febcc49cb43602a0fbea25358127a6e878bca90bd5faff3c2df4fc85f4a2b","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-17","leadSponsor":"Xerient Pharma","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":36,"enrolmentType":"ESTIMATED","siteCount":5,"recruitingSiteCount":5,"countries":["United States"]}],"started":"2026-01-01","startedType":"actual","enrolled":36,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07157033/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"amifostine","kind":"drug","name":"Amifostine","route":"/drugs/amifostine/"}]}}